Edition:
United Kingdom

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

5.37USD
22 Oct 2018
Change (% chg)

-- (--)
Prev Close
$5.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
434,270
52-wk High
$9.41
52-wk Low
$5.03

Chart for

About

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging... (more)

Overall

Beta: 3.54
Market Cap(Mil.): $515.08
Shares Outstanding(Mil.): 70.27
Dividend: --
Yield (%): --

Financials

  PGNX.OQ Industry Sector
P/E (TTM): -- 85.35 33.64
EPS (TTM): -0.06 -- --
ROI: -3.04 0.18 14.27
ROE: -5.26 1.14 15.99

FDA approves Progenics' treatment for rare adrenal gland tumors

The U.S. Food and Drug Administration (FDA) on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of rare adrenal gland tumors, making it the first drug approved in the United States for this use.

30 Jul 2018

UPDATE 1-FDA approves Progenics' treatment for rare adrenal gland tumors

July 30 The U.S. Food and Drug Administration (FDA) on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of rare adrenal gland tumors, making it the first drug approved in the United States for this use.

30 Jul 2018

FDA approves Progenics' treatment for two rare tumors

July 30 The U.S. Food and Drug Administration (FDA) on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of tumors.

30 Jul 2018

BRIEF-Progenics Pharmaceuticals Announces Q1 Loss Per Share $0.19

* PROGENICS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE

09 May 2018

Earnings vs. Estimates